BD: Growth in Bio Led to Launch of Neopak Prefillable Syringe
As the industry shifts its intention from traditional small molecules to larger, complex molecules in vaccines targeting chronic diseases, BD Medical – a subsidiary of BD (Becton, Dickinson and Company) - has launched its Neopak syringe specifically made for use with the BD Physioject autoinjector for the administration of biopharmaceutical injectables.
Speaking with in-Pharmatechnologist.com, Amanda Davis – Senior Product Manager at BD Medical – said as biotech drugs continue to increase in prevalence, “the biotechnology market along with regulatory agencies have set very specific requirements for drug delivery of biologics in terms of quality, safety and functionality that surpass requirements from even five years ago.”
As administration of care moves away from a healthcare setting and into the patient’s home, there has been an increase in demand for autoinjectors to make self-injection easier and more comfortable.
Davis said the system offers several advantages in the injection of biologics to reduce the risk associated with primary container and drug interactions, including minimising “the silicone level to reduce subvisible particles, while maintaining proper glide force to ensure autoinjector functionality.”
“We believe that BD Neopak Glass Prefillable Syringe is a true step change in prefillable glass syringe quality performance, utilizing quality by design engineering,” she continued.
“Additionally, because BD manufactures both the glass prefillable syringe as well as the autoinjector, we are uniquely positioned to enhance container and device integration for our customers and ensure robust delivery systems for patients.”
The large range of biologics in development and seven of the ten bestsellers worldwide are biologics, according to the company, and thus Davis added that BD had “seen tremendous interest and demand” from its biopharmaceutical clients.
BD recently entered the pharmaceutical world, creating a new generic wing after the FDA approved its first injectable drug. However, if the development of biologics was a reality for BD, Davis told this publication that the company “has no plans to develop biosimilars.”
